Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
Purity: ≥98%
Garenoxacin mesylate hydrate (BMS-284756; tradename: Geninax), the hydrated and mesylate salt of Garenoxacin, is a quinolone-based oral bioavailable antibiotic used to treat both Gram-positive and Gram-negative bacterial infections.
Targets |
Gyrase ( IC50 = 1.25 μg/mL ); TOPO IV ( IC50 = 1.5-2.5 μg/mL ); Quinolone
|
---|---|
ln Vitro |
Garenoxacin (BMS284756) (0-8 days) inhibits the growth of tested strains of mycoplasma and ureaplasma with MIC90s ≤0.25 μg/mL[1].
Garenoxacin (48 h) has MICs of 0.0128-4.0 μg/mL, which inhibits both wild type and mutant S. aureus[2]. Garenoxacin has an IC50 of 1.25 to 2.5 μg/mL for topoisomerase IV and 1.25 μg/mL for gyrase from S. aureus, respectively. Garenoxacin has a low tendency to selectively enrich fluoroquinolone-resistant mutants from S. aureus isolates that are susceptible to ciprofloxacin[3]. |
ln Vivo |
Garenoxacin (12.5-50 mg/kg; s.c.; once) is very effective against both the wild-type strain and mutants carrying a single mutation in a mouse pneumonia model with S. pneumonia infection[4].
Garenoxacin (10 and 30 mg/kg; p.o.; once) significantly increases the time that BALB/c female mice survive experimental secondary pneumococcal pneumonia caused by S. pneumoniae D-979[5] while also reducing the number of viable cells in the lungs. |
Cell Assay |
Cell Line: M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp.
Incubation Time: 24 h for Ureaplasma spp., 48 h for M. hominis, 4 to 8 days for M. pneumonia Result: Showed inhibition with MIC90s of 0.031 μg/mL, ≤0.008 μg/mL, ≤0.008 μg/mL and 0.25 μg/mL against M. pneumonia, M. fermentans, M. hominis and Ureaplasma spp. strains, respectively. |
Animal Protocol |
Swiss mice with S. pneumonia infection
12.5, 25 and 50 mg/kg Subcutaneous injection, once |
References |
|
Molecular Formula |
C24H26F2N2O8S
|
---|---|
Molecular Weight |
540.53
|
Exact Mass |
540.14
|
Elemental Analysis |
C, 53.33; H, 4.85; F, 7.03; N, 5.18; O, 23.68; S, 5.93
|
CAS # |
223652-90-2
|
Related CAS # |
194804-75-6; 223652-90-2 (mesylate hydrate); 223652-82-2 (mesylate)
|
Appearance |
Solid powder
|
SMILES |
C[C@@H]1C2=C(CN1)C=C(C=C2)C3=C(C4=C(C=C3)C(=O)C(=CN4C5CC5)C(=O)O)OC(F)F.CS(=O)(=O)O.O
|
InChi Key |
IGTHEWGRXUAFKF-NVJADKKVSA-N
|
InChi Code |
InChI=1S/C23H20F2N2O4.CH4O3S.H2O/c1-11-15-5-2-12(8-13(15)9-26-11)16-6-7-17-19(21(16)31-23(24)25)27(14-3-4-14)10-18(20(17)28)22(29)30;1-5(2,3)4;/h2,5-8,10-11,14,23,26H,3-4,9H2,1H3,(H,29,30);1H3,(H,2,3,4);1H2/t11-;;/m1../s1
|
Chemical Name |
1-cyclopropyl-8-(difluoromethoxy)-7-[(1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl]-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid;hydrate
|
Synonyms |
BMS-284756-01; BMS284756-01; T-3811ME; T3811ME; Garenoxacin mesylate; Garenoxacin mesylate hydrate
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 2~100 mg/mL (4.7~185.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8500 mL | 9.2502 mL | 18.5004 mL | |
5 mM | 0.3700 mL | 1.8500 mL | 3.7001 mL | |
10 mM | 0.1850 mL | 0.9250 mL | 1.8500 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.